Skip to main content
Topas Therapeutics GmbH

Falkenried 88, Haus A
20251 Hamburg GERMANY

+49 40 302089010

Tag: Boehringer Ingelheim Venture Fund

Sebastian Kreuz, PhD

Sebastian joined the Boehringer Ingelheim Venture Fund (BIVF) in 2019. With over 15 years of experience in translational research and drug discovery within the pharmaceutical industry, he has a strong scientific background in various disease areas and is familiar with a broad range of therapeutic modalities. From 2015 to 2019, he worked in the Research Beyond Borders department at Boehringer Ingelheim (BI) to implement a platform concept for viral vector-based gene therapy as a novel therapeutic modality for BI. During this time, he established a global collaboration network involving collaborations in Europe, China and the US. Before that, Sebastian held a variety of positions within the BI R&D organization. He studied technical biology at the University of Stuttgart and holds a PhD in molecular biology and immunology. In addition to Topas Therapeutics, he serves as a board member for Abalos Therapeutics GmbH, Rewind Therapeutics and Quantro Therapeutics GmbH.